深 圳 市 海 王 英 特 龍 生 物 技 術 股 份 有 限 公 司 SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED* （於中華人民共和國註冊成立之股份有限公司） （股份代號：8329） 截至二零二三年九月三十日止九個月 之第三季度業績公告 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他在聯交所上市的公司帶有 較高投資風險。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮後方 可作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板買賣之證券承受較大的市 場波動風險，同時無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本公告的內容概不負責，對其準確性或完整性亦不發表任何 聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失 承擔任何責任。 本公告的資料乃遵照聯交所的《GEM證券上市規則》（「GEM上市規則」）而刊載，旨在提供有關深圳市 海王英特龍生物技術股 ...

Financial Performance - The Group's profit after tax increased from approximately RMB 17,835,000 for the corresponding period of last year to approximately RMB 31,090,000 for the Reporting Period, representing an increase of approximately 74.32%[17] - Profit attributable to the owners of the Company increased from approximately RMB 20,344,000 for the corresponding period of last year to approximately RMB 29,881,000 for the Reporting Period, representing an increase of approximately 46.88%[17] - For the six months ended June 30, 2023, the profit attributable to owners of the Company was approximately RMB29,881,000, compared to RMB20,344,000 for the same period in 2022, representing an increase of 46.8%[80] - Basic earnings per share for the six months ended June 30, 2023, was RMB0.0178, up from RMB0.0121 for the same period in 2022, reflecting a growth of 47.1%[80] - Profit before taxation for the six months ended June 30, 2023, was RMB 36,474,000, up 44.2% from RMB 25,281,000 in the same period of 2022[122] - Profit and total comprehensive income for the period attributable to owners of the company was RMB 29,881,000 for the six months ended June 30, 2023, compared to RMB 20,344,000 in 2022[124] - For the six months ended June 30, 2023, the total comprehensive income was RMB 31,090, an increase from RMB 17,835 for the same period in 2022, representing a growth of 74.5%[128] Revenue and Sales - Revenue for the six months ended June 30, 2023, was RMB 555,531,000, an increase of 26.6% compared to RMB 438,869,000 for the same period in 2022[122] - Revenue from the manufacturing and selling of medicines was RMB 407,492,000, up 31.4% from RMB 310,182,000 year-on-year[160] - The sales and distribution of medicines and healthcare products generated RMB 148,039,000 in revenue, an increase from RMB 128,687,000 in the previous year[160] - For the six months ended June 30, 2023, total revenue reached RMB 555,531,000, a 26.6% increase from RMB 438,869,000 in the same period of 2022[160] - The reportable segment revenue was RMB 602,183,000, an increase from RMB 461,618,000 in the same period of 2022, representing a growth of approximately 30.4%[171] Expenses and Costs - The Group's sales and distribution expenses during the Reporting Period amounted to approximately RMB147,759,000, representing an increase of approximately 36.55% compared to RMB108,208,000 in the same period last year[39] - Other operating expenses totaled approximately RMB24,053,000, reflecting an increase of approximately 15.97% from RMB20,740,000 for the corresponding period of last year, primarily due to higher impairment of inventories and increased research and development expenses[40] - Staff costs, including directors' remuneration, amounted to approximately RMB73,137,000 during the Reporting Period, with salary increases and improved benefits implemented to maintain competitiveness[46] - Administrative expenses for the six months ended June 30, 2023, were RMB 41,207,000, slightly decreased from RMB 41,600,000 in 2022[122] Assets and Liabilities - Trade receivables as of June 30, 2023, amounted to RMB210,517,000, an increase from RMB177,007,000 as of December 31, 2022, representing a growth of 18.9%[82] - The total amount of trade and other receivables as of June 30, 2023, was RMB373,628,000, compared to RMB341,968,000 as of December 31, 2022, reflecting an increase of 9.3%[82] - Net current assets as of June 30, 2023, were RMB 551,898,000, an increase from RMB 482,366,000 at the end of 2022[127] - Total assets less current liabilities as of June 30, 2023, amounted to RMB 1,067,985,000, compared to RMB 1,035,507,000 at the end of 2022[127] - The company's total assets as of June 30, 2023, were RMB 1,036,394, an increase from RMB 962,235 at the end of June 2022, indicating a growth of 7.7%[128] - The total liabilities for reportable segments as of June 30, 2023, were RMB 664,537,000, a slight decrease from RMB 678,732,000 at the end of 2022[195] Inventory and Cash Flow - The Group's inventory write-down for the six months ended 30 June 2023 was RMB 6,013,000, compared to RMB 2,047,000 for the same period in 2022[2] - Inventories as of June 30, 2023, were RMB 222,779, an increase from RMB 203,023 at the end of June 2022, representing a rise of 9.7%[139] - The company reported a net cash used in operating activities of RMB 52,320 for the six months ended June 30, 2023, compared to a net cash generated of RMB 64,462 in the same period of 2022[143] - The company reported a net decrease in cash and cash equivalents of RMB 52,656,000 for the period, compared to an increase of RMB 40,113,000 in the same period last year[145] Research and Development - The Group has developed new medicines such as Doxofylline Injection and Concentrated Sodium Potassium Magnesium Calcium Injection, both of which have obtained approval[10] - The Group's research and development expenses are eligible for a super deduction of 200% for tax purposes, an increase from 175% in the previous year[94] - The group aims to enhance its market presence through ongoing research and development in modern biological technology[148] Corporate Governance - The Company confirmed compliance with Non-Competition Undertakings during the Reporting Period[55] - All Directors confirmed adherence to the "Required Standard of Dealings" and the Company's code of conduct regarding securities transactions[58] - The Company has adopted a code of conduct for securities transactions by Directors that meets the standards set out in the GEM Listing Rules[56] Shareholder Information - As of June 30, 2023, Neptunus Bio-engineering held approximately 73.51% of the entire issued share capital of the Company, with 70.38% directly held and 3.13% indirectly held through Shenzhen Neptunus Oriental Investment Company Limited[49] - Neptunus Group was deemed to be interested in 1,233,464,500 domestic shares of the Company, representing a significant portion of the issued share capital[52] - The Company has not adopted any share option schemes or granted any share options, convertible securities, warrants, or similar rights as of June 30, 2023[50] Taxation - The Group's subsidiaries in the PRC are subject to a preferential enterprise income tax rate of 15% due to their qualification as "High and New Technology Enterprises"[93] - The Group had no assessable profits subject to Hong Kong Profits Tax during the Reporting Period, maintaining a tax provision of zero[96]

深 圳 市 海 王 英 特 龍 生 物 技 術 股 份 有 限 公 司 SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED* （於中華人民共和國註冊成立之股份有限公司） （股份代號：8329） 截至二零二三年六月三十日止六個月 之中期業績公告 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他在聯交所上市的公司帶有較高投資風險。有意投資的人士應了解投資於 該等公司的潛在風險，並應經過審慎周詳的考慮後方可作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於聯交所主板買賣之證券承受較大的市場波動風險，同時無法保證在GEM買 賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本公告的資料乃遵照聯交所的《GEM證券上市規則》（「GEM上市規則」）而刊載，旨在提供有關深圳市海王英特龍生物技術股份有 ...

Financial Performance - The Company reported a revenue of RMB 299,718,000 for the three months ended March 31, 2023, representing a 38.9% increase compared to RMB 215,698,000 in the same period of 2022[9]. - Gross profit for the reporting period was RMB 140,803,000, up 43.4% from RMB 97,543,000 year-over-year[9]. - Profit before taxation increased to RMB 22,309,000, a 50.1% rise from RMB 14,842,000 in the previous year[10]. - The net profit attributable to the owners of the Company was RMB 16,264,000, compared to RMB 10,541,000 in the same period last year, marking a 54.5% increase[10]. - Basic and diluted earnings per share for the period were RMB 0.97 cents, up from RMB 0.63 cents in the prior year, reflecting a 54% increase[10]. - The Company reported total comprehensive income for the period of RMB 19,198,000, which is a 67.1% increase from RMB 11,508,000 in the previous year[10]. Revenue Breakdown - Revenue from manufacturing and selling medicines was RMB 216,653,000, up 43.7% from RMB 150,703,000 in the previous year[21]. - Revenue from sales and distribution of medicines and healthcare products increased to RMB 83,065,000, a rise of 28.0% from RMB 64,995,000 in 2022[21]. - Other revenue totaled RMB 3,167,000, which is a 40.4% increase from RMB 2,256,000 in the prior year[24]. - The Group's revenue primarily comes from the sale of medicines across various therapeutic areas, including oncology and cardiovascular systems[44][46]. Expenses - Selling and distribution expenses rose to RMB 87,457,000, an increase of 63.6% from RMB 53,440,000 in the previous year[9]. - Administrative expenses remained relatively stable at RMB 22,959,000, compared to RMB 22,364,000 in the same period last year[10]. - Staff costs increased to RMB 38,278,000, reflecting a rise of 2.3% from RMB 37,401,000 in the same period last year[27]. - Research and development costs were RMB 7,319,000, which is an increase of 6.1% compared to RMB 6,897,000 in the previous year[30]. - Other operating expenses amounted to approximately RMB 9,955,000, representing an increase of approximately 20.50% from RMB 8,261,000 for the corresponding period last year[65]. Taxation - Current tax provision for the period was RMB 3,413,000, compared to RMB 3,219,000 in the same period of 2022[34]. - The effective tax rate for the qualified high technology enterprises was 15%, while other subsidiaries were subject to a 25% rate[35]. Equity and Shareholding - The total equity of the Company as of March 31, 2023, was RMB 1,024,502,000, reflecting growth from RMB 955,908,000 at the same time last year[11]. - As of March 31, 2023, Neptunus Bio-engineering holds approximately 73.51% of the entire issued share capital of the Company, with 70.38% directly held and 3.13% indirectly held through Shenzhen Neptunus Oriental Investment Company Limited[81]. - Neptunus Bio-engineering holds 1,181,000,000 domestic shares, representing 94.33% of all domestic shares and 70.38% of the company's issued share capital[92]. Corporate Governance - The Company has established an Audit Committee to review financial statements and provide suggestions to the Board[108]. - The Audit Committee has reviewed the unaudited consolidated results for the Reporting Period[109]. - The Company has complied with the Corporate Governance Code during the Reporting Period[116]. - The roles of the Chairman and General Manager are separate, with Mr. Zhang Feng serving as the current Chairman[110]. - The Company is in the process of identifying a suitable candidate for the General Manager position following the resignation of Mr. Zhou Hang[115]. - The Company is committed to maintaining compliance with GEM Listing Rules[116]. Research and Development - The Group's research and development efforts focus on both independent projects and collaborations with external institutions, emphasizing innovation in generic medicines and new drug development[49][50]. - The Group owns a total of 35 patents for inventions, with four products having passed the consistency evaluation, including Sodium Bicarbonate Tablets and Metformin Hydrochloride Tablets[49][50]. - The Group has received approvals for new products, including Doxofylline Injection and Concentrated Sodium Potassium Magnesium Calcium Injection, enhancing its product portfolio[49][50]. Dividends and Share Options - No dividends were recommended for the reporting period, consistent with the previous year[37][40]. - The Company and its subsidiaries have not adopted any share option scheme or granted any options, convertible securities, or warrants as of March 31, 2023[83]. - During the reporting period, no Directors or supervisors were granted any share options, warrants, or convertible bonds[84].

深 圳 市 海 王 英 特 龍 生 物 技 術 股 份 有 限 公 司 SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED* （於中華人民共和國註冊成立之股份有限公司） （股份代號：8329） 截至二零二三年三月三十一日止三個月的第一季度業績公告 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他在聯交所上市的公司帶有 較高投資風險。有意投資的人士應瞭解投資於該等公司的潛在風險，並應經過審慎周詳的考慮後方 可作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板買賣的證券承受較大的市 場波動風險，同時無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本公告的內容概不負責，對其準確性或完整性亦不發表任何 聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失 承擔任何責任。 本公告乃遵照聯交所的《GEM證券上市規則》（「GEM上市規則」）而刊載，旨在提供有關深圳市海王英 特龍生物技術股份有限 ...

Business Operations and Market Environment - The Group's business activities resumed rapidly as COVID-19 measures transitioned to a "Class B infection" management, contributing to the overall growth trend of the national economy [16]. - The pharmaceutical industry in China is undergoing significant reforms, including centralized procurement and quality consistency evaluations for generic drugs, which the Group is adapting to [16]. - The Group is focused on enhancing its operational modes in line with key reform arrangements in the pharmaceutical sector [16]. - The Group experienced fluctuating market demand for drugs due to rapid changes in COVID-19 prevention policies, which provided valuable experience in production and supply chain management during epidemic outbreaks [20]. - The Group's pharmaceutical subsidiaries actively participated in drug bidding across various provinces, enhancing market allocation and circulation [35]. Product Development and Sales - The Group's principal activities include research and development, manufacturing, and selling of medicines and healthcare food products, focusing on therapeutic areas such as oncology, cardiovascular, respiratory, digestive, and mental disorders [26]. - By the end of 2022, the Group had 366 Guo Yao Zhun Zi approval documents for Chinese and chemical medicines at its Fuzhou Production Base, with 235 varieties included in the National Medical Insurance Catalogue and 146 in the National Essential Drug List [27]. - The Group has developed various new drugs and exclusive products, including anti-cancer and immune-enhancing medications [31]. - The Group's medicines and healthcare food products division focused on integrated planning and adjusted sales strategies, resulting in a smaller year-on-year revenue decrease compared to the first half of the year [41]. - The Group's sales channels expanded to include direct sales to terminal chain pharmacies, increasing market reach [35]. Financial Performance - The Group's total revenue for the Year was approximately RMB986,691,000, representing an increase of approximately 17.63% compared to the previous year [51]. - Revenue from the manufacturing and selling of medicines segment was approximately RMB694,840,000, accounting for approximately 70.42% of total revenue, with a year-on-year increase of approximately 36.18% [51]. - Revenue from the sales and distribution of medicines and healthcare products segment decreased by approximately 11.18% to approximately RMB291,851,000, accounting for approximately 29.58% of total revenue [51]. - The Group's gross profit margin remained stable at approximately 45%, with gross profit increasing by approximately 18.72% to approximately RMB444,142,000 [52]. - Profit after tax increased by approximately 86.06% to approximately RMB63,830,000, with profit attributable to owners increasing by approximately 51.14% to approximately RMB54,346,000 [60]. Cost Management and Investments - The Group is committed to increasing investment in production and quality assurance systems, as well as in the research and development of new drugs and drug quality consistency evaluation [21]. - The Group has strengthened cost control and marketing efforts for generic and basic drugs, ensuring competitive pricing and availability in the market [20]. - The Group's strategic focus includes cost reduction and efficiency enhancement to achieve stable and high-quality development [36]. - The Group is focused on enhancing core competitiveness and expanding its investment in product manufacturing, quality assurance, and R&D of new medicines [46]. Governance and Management - The Board believes that with continued governance improvements and management efforts, the Group's business will develop positively in the future [21]. - The management team includes experienced professionals with backgrounds in finance and pharmaceuticals [104]. - The Board includes a diverse group of directors with significant industry experience [108]. - The company has a strong board with independent non-executive directors, including Mr. Yick Wing Fat, who has over 30 years of experience in auditing and corporate advisory services [114]. - The appointment of experienced directors is expected to strengthen the company's strategic direction and operational efficiency [119]. Human Resources and Staff Costs - The Group employed a total of 1,458 staff as of December 31, 2022, compared to 1,401 in the previous year [91]. - The Group's total staff costs, including directors' remuneration, amounted to approximately RMB 151,268,000, an increase from approximately RMB 120,083,000 in 2021 [92]. - Administrative expenses rose by approximately 16.39% to approximately RMB93,733,000, mainly due to increased staff costs and expenses related to the acquisition of Neptunus Zhongxin [54]. Future Outlook and Strategic Initiatives - The Group is exploring external investment opportunities in traditional Chinese medicine to bolster future development in this sector [20]. - The company aims to leverage its management's diverse expertise to drive future growth and market expansion [116]. - The company continues to focus on enhancing its market position through strategic investments and partnerships in the pharmaceutical industry [113].

深 圳 市 海 王 英 特 龍 生 物 技 術 股 份 有 限 公 司 SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED* （於中華人民共和國註冊成立的股份有限公司） （股份代號：8329） 截至二零二二年十二月三十一日止年度全年業績公佈 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他在主板上市的公司帶有較 高投資風險。有意投資的人士應瞭解投資於該等公司的潛在風險，並應經過審慎周詳的考慮後方可 作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板買賣的證券承受較大的市 場波動風險，同時無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本公告的內容概不負責，對其準確性或完整性亦不發表任何 聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失 承擔任何責任。 本公告乃遵照聯交所的《GEM證券上市規則》（「GEM上市規則」）而刊載，旨在提供有關深圳市海王英 特龍生物技術股份有限公司（「 ...

Financial Performance - Revenue for the nine months ended September 30, 2022, was RMB 689,399,000, an increase of 15.5% compared to RMB 596,776,000 for the same period in 2021[12]. - Gross profit for the nine months ended September 30, 2022, was RMB 304,560,000, representing a 10.6% increase from RMB 275,364,000 in the previous year[12]. - Profit from operations for the nine months ended September 30, 2022, was RMB 51,909,000, up 41.7% from RMB 36,634,000 in 2021[12]. - Profit before taxation for the nine months ended September 30, 2022, was RMB 47,335,000, an increase of 37.3% compared to RMB 34,441,000 in the same period of 2021[14]. - Net profit attributable to owners of the Company for the nine months ended September 30, 2022, was RMB 35,886,000, a rise of 42.5% from RMB 25,207,000 in 2021[14]. - Earnings per share for the nine months ended September 30, 2022, was RMB 2.14 cents, compared to RMB 1.50 cents for the same period in 2021[14]. - The Company reported a total comprehensive income of RMB 34,209,000 for the nine months ended September 30, 2022, compared to RMB 26,661,000 in 2021, marking a 28.3% increase[14]. - The profit and total comprehensive income for the period ended September 30, 2022, was RMB 34,209,000, compared to RMB 25,207,000 for the same period in 2021, indicating a year-over-year increase of approximately 35.7%[17]. - For the three months ended September 30, 2022, total revenue was RMB 250,530,000, an increase of 21.8% compared to RMB 205,582,000 for the same period in 2021[33]. - For the three-month period ended September 30, 2022, the profit attributable to owners of the Company was approximately RMB 15,542,000, representing an increase of 179% compared to RMB 5,560,000 for the same period in 2021[50]. - For the nine-month period ended September 30, 2022, the profit attributable to owners of the Company was approximately RMB 35,886,000, an increase of 42.5% from RMB 25,207,000 for the same period in 2021[50]. Expenses and Costs - Selling and distribution expenses for the nine months ended September 30, 2022, were RMB 174,350,000, a decrease of 3.2% from RMB 180,138,000 in 2021[12]. - Administrative expenses for the nine months ended September 30, 2022, increased to RMB 64,360,000 from RMB 55,949,000 in 2021, reflecting a rise of 15.1%[12]. - Other operating expenses amounted to approximately RMB 31,766,000, an increase of approximately 21.53% from RMB 26,139,000 for the corresponding period of last year[82]. - Finance costs increased by approximately 108.57% to approximately RMB 4,574,000 from RMB 2,193,000 for the corresponding period of last year[83]. - Staff costs for the three months ended September 30, 2022, increased to RMB 35,712,000, a rise of 37.7% compared to RMB 25,940,000 in the same period of 2021[39]. - Research and development costs for the three months ended September 30, 2022, were RMB 7,831,000, an increase of 16.9% from RMB 6,699,000 in 2021[42]. Equity and Assets - As of September 30, 2022, the total equity of the company was RMB 975,682,000, an increase from RMB 942,867,000 as of September 30, 2021, reflecting a growth of approximately 3.5% year-over-year[17]. - The retained earnings as of September 30, 2022, were RMB 282,071,000, up from RMB 236,109,000 as of September 30, 2021, representing a growth of about 19.5%[17]. - The company completed the acquisition of a subsidiary, which resulted in a decrease of RMB 13,126,000 in equity[17]. - The total assets of the company as of September 30, 2022, were not explicitly stated but can be inferred from the total equity and liabilities[17]. Revenue Segmentation - Revenue from manufacturing and selling medicines was RMB 174,975,000 for the three months ended September 30, 2022, up from RMB 130,547,000 in the same period of 2021, representing a growth of 34.0%[33]. - Revenue from sales and distribution of medicines and healthcare products reached RMB 75,555,000 for the three months ended September 30, 2022, slightly up from RMB 75,035,000 in the same period of 2021[33]. - Revenue from the manufacturing and selling of medicines segment increased by approximately 33.17%, amounting to approximately RMB 485,157,000, which is about 70.37% of the Group's total revenue[74]. - Revenue from the sales and distribution of medicines and healthcare products segment decreased by approximately 12.14%, totaling approximately RMB 204,242,000, which is about 29.63% of the Group's total revenue[74]. Corporate Governance and Compliance - The Company has adopted a code of conduct regarding securities transactions by Directors, confirming compliance by all Directors during the Reporting Period[135]. - The roles of the Chairman and General Manager are separate, with Mr. Zhang Feng serving as the current Chairman[139]. - The Company is in the process of identifying a suitable candidate to fill the vacancy of the General Manager[140]. - The Board will continue to enhance the standard of corporate governance to ensure responsible business operations[146]. - Neptunus Bio-engineering confirmed compliance with the Non-Competition Undertakings during the Reporting Period[131]. Research and Development - The Group's research and development efforts have resulted in 22 patents for invention, with 4 products having passed the quality consistency evaluation for generic drugs[61]. - The evaluation of Doxofylline Injection has been approved, and the Concentrated Sodium Potassium Magnesium Calcium Injection is pending approval[61]. Shareholding Structure - The controlling shareholder, Neptunus Bio-engineering, held approximately 73.51% of the entire issued share capital of the company, with 70.38% directly held and 3.13% indirectly held[93]. - As of September 30, 2022, Neptunus Bio-engineering holds 1,181,000,000 domestic shares, representing approximately 94.33% of the company's issued share capital[111]. - Neptunus Group is deemed to be interested in 1,233,464,500 domestic shares, which accounts for approximately 98.52% of the company's issued share capital[113]. - The company has not adopted any share option scheme or granted any options, convertible securities, or warrants as of September 30, 2022[111].

Financial Performance - Revenue for the six months ended June 30, 2022, increased to RMB 438,869,000, up 12.1% from RMB 391,194,000 in the same period of 2021[12] - Gross profit for the six months ended June 30, 2022, was RMB 187,858,000, representing a slight increase of 1.4% compared to RMB 185,303,000 in 2021[12] - Profit from operations for the six months ended June 30, 2022, rose to RMB 28,443,000, an increase of 6.2% from RMB 26,770,000 in the previous year[12] - Profit before taxation for the six months ended June 30, 2022, was RMB 25,281,000, compared to RMB 26,032,000 in the same period of 2021, indicating a decrease of 2.9%[12] - The total comprehensive income for the period attributable to owners of the Company was RMB 20,344,000, up from RMB 19,647,000 in 2021, reflecting an increase of 3.5%[14] - Basic and diluted earnings per share for the six months ended June 30, 2022, were RMB 1.21 cents, compared to RMB 1.17 cents in the same period of 2021, marking a growth of 3.4%[14] Expenses and Costs - Selling and distribution expenses for the six months ended June 30, 2022, were RMB 108,208,000, a decrease of 10.7% from RMB 121,177,000 in 2021[12] - Administrative expenses for the six months ended June 30, 2022, increased to RMB 41,600,000, up from RMB 34,465,000 in the previous year, representing a rise of 20.5%[12] - Other revenue for the six months ended June 30, 2022, was RMB 10,643,000, down from RMB 12,021,000 in 2021, indicating a decline of 11.5%[12] - The Company reported a finance cost of RMB 3,162,000 for the six months ended June 30, 2022, compared to RMB 738,000 in the same period of 2021, reflecting a significant increase of 328.5%[12] Assets and Liabilities - As of June 30, 2022, total assets amounted to RMB 992,845,000, an increase from RMB 972,080,000 as of December 31, 2021, reflecting a growth of approximately 2.8%[18] - Current liabilities increased to RMB 339,318,000 from RMB 335,490,000, indicating a slight rise of about 0.5%[18] - Net current assets improved to RMB 434,767,000, up from RMB 404,489,000, representing an increase of approximately 7.5%[18] - Total equity reached RMB 962,235,000, compared to RMB 944,400,000 at the end of 2021, marking a growth of about 1.9%[20] - The company's retained earnings rose to RMB 266,279,000, up from RMB 245,935,000, reflecting an increase of approximately 8.3%[23] - Trade and other payables increased to RMB 243,154,000 from RMB 206,449,000, showing a significant rise of about 17.7%[18] - Inventories grew to RMB 175,182,000, compared to RMB 157,954,000, indicating an increase of approximately 10.9%[18] - Interest-bearing bank borrowings decreased to RMB 66,070,000 from RMB 101,137,000, a reduction of about 34.7%[18] Cash Flow - Operating cash flows before changes in working capital increased to RMB 50,567,000 in 2022 from RMB 37,856,000 in 2021, representing a growth of 33.5%[26] - Net cash generated from operating activities was RMB 64,462,000 in 2022, compared to a net cash used of RMB 65,036,000 in 2021, indicating a significant turnaround[26] - Cash generated from operations, after income tax paid, was RMB 68,663,000, with income tax paid amounting to RMB 4,201,000[26] - Net cash generated from investing activities was RMB 17,240,000 in 2022, a recovery from a net cash used of RMB 64,412,000 in 2021[28] - The company reported a net cash used in financing activities of RMB 41,589,000 in 2022, compared to RMB 20,481,000 in 2021, indicating increased financing costs[28] - Cash and cash equivalents at the end of the period increased to RMB 267,257,000 in 2022 from RMB 261,956,000 in 2021, showing a slight growth[28] Revenue Breakdown - Revenue from the manufacturing and selling of medicines reached RMB 310,182,000 for the six months ended June 30, 2022, an increase of 32.5% compared to RMB 233,766,000 for the same period in 2021[44] - Revenue from sales and distribution of medicines and healthcare products was RMB 128,687,000 for the six months ended June 30, 2022, compared to RMB 157,428,000 in the same period of 2021, showing a decline of 18.3%[44] - The total revenue for the three months ended June 30, 2022, was RMB 223,171,000, an increase of 30% from RMB 171,905,000 in the same period of 2021[44] - Reportable segment revenue for the six months ended June 30, 2022, was RMB 461,618,000, an increase from RMB 412,103,000 in 2021, representing a growth of 12%[60] - Revenue from external customers in the manufacturing and selling of medicines segment was RMB 310,182,000 for the first half of 2022, compared to RMB 233,766,000 in 2021, marking a 32.6% increase[51] Research and Development - Research and development costs for the six months ended June 30, 2022, were RMB 6,592,000, slightly up from RMB 6,082,000 in the same period of 2021, showing an increase of approximately 8.4%[79] - The Group is entitled to claim 175% of the research and development expenses as tax-deductible expenses under the "Super Deduction" policy, applicable to three subsidiaries[87] Related Party Transactions - Related party transactions for the six months ended June 30, 2022, included sales of goods amounting to RMB 5,800,000 with Shandong Neptunus Yinhe Pharmaceutical Company Limited[125] - The company’s related party transactions were conducted under normal business terms, consistent with those charged to third-party suppliers and customers[146] Future Outlook - The company expects revenue guidance for Q3 2023 to be between $5.5 billion and $5.7 billion, indicating a potential growth of 6% to 9%[200] - The company plans to enter the Asian market by Q4 2023, targeting a revenue contribution of $1 billion in the first year[200]

Financial Performance - Revenue for Q1 2022 was RMB 215,698,000, a decrease of 1.3% compared to RMB 219,289,000 in Q1 2021[8] - Gross profit for the period was RMB 97,543,000, down 17.5% from RMB 118,147,000 in the same period last year[8] - Profit before taxation decreased to RMB 14,842,000, a decline of 33.1% from RMB 22,312,000 in Q1 2021[11] - Net profit for the period was RMB 11,508,000, down 36.5% compared to RMB 18,073,000 in Q1 2021[11] - Earnings per share for the period was RMB 0.63, a decrease from RMB 0.93 in the same period last year[11] - The total comprehensive income attributable to owners of the company was RMB 10,541,000, down from RMB 15,648,000 in Q1 2021[11] - For the three months ended 31 March 2022, the Group reported an unaudited profit attributable to owners of approximately RMB 10,541,000, compared to approximately RMB 15,648,000 for the same period in 2021, indicating a decrease of about 32.5%[54] - The Group's profit after tax for the Reporting Period was approximately RMB 11,508,000, a decrease of approximately 36.32% from RMB 18,073,000 in the corresponding period last year[88] - Profit attributable to the owners of the Company was approximately RMB 10,541,000, representing a decrease of approximately 32.64% from RMB 15,648,000 in the corresponding period last year[88] Revenue Breakdown - Revenue from the manufacturing and selling of medicines was RMB 150,703,000, up 23.7% from RMB 121,789,000 in the previous year[31] - Revenue from the sales and distribution of healthcare products was RMB 64,995,000, down 33.3% from RMB 97,500,000 in the previous year[31] - Approximately RMB 150,703,000, which amounted to approximately 69.87% of the Group's total revenue, was derived from the manufacturing and selling of medicines segment, while approximately RMB 64,995,000, which amounted to approximately 30.13%, was from the sales and distribution of medicines and healthcare products segment[78] - Revenue from the manufacturing and selling of medicines segment increased by approximately 23.74% compared to the corresponding period of last year, while revenue from the sales and distribution of medicines and healthcare products segment decreased by approximately 33.34%[82] Expenses - Selling and distribution expenses were reduced to RMB 53,440,000, down 30.7% from RMB 77,118,000 in Q1 2021[8] - Administrative expenses increased to RMB 22,364,000, up 30.4% from RMB 17,175,000 in Q1 2021[8] - Staff costs increased to RMB 37,401,000, a rise of 42.6% from RMB 26,232,000 in the same period of 2021[39] - Depreciation of property, plant, and equipment was RMB 5,764,000, an increase of 40.1% from RMB 4,113,000 in the previous year[42] - Other operating expenses amounted to approximately RMB 8,261,000, representing an increase of approximately 36.30% from RMB 6,061,000 for the corresponding period of last year[86] - Administrative expenses during the Reporting Period were approximately RMB 22,364,000, an increase of approximately 30.21% from RMB 17,175,000 in the same period last year, primarily due to increased employee costs and expenses related to the acquisition of Haiwang Zhongxin[90] - Other operating expenses were approximately RMB 8,261,000, up approximately 36.30% from RMB 6,061,000 in the previous year, mainly due to increased R&D expenses following the acquisition of Haiwang Zhongxin[90] Financial Costs - Finance costs significantly decreased to RMB 1,650,000 from RMB 11,000 in Q1 2021[11] - Finance costs amounted to approximately RMB 1,650,000, representing an increase of approximately 14,900% from approximately RMB 11,000 for the corresponding period of last year[87] - Financial costs for the Reporting Period were approximately RMB 1,650,000, a significant increase of approximately 14,900% from RMB 11,000 in the same period last year, attributed to increased bank loan interest expenses from the acquisition[90] Corporate Governance - The Board does not recommend the payment of any dividend for the Reporting Period, consistent with the previous year[54] - The Company has complied with the requirements under the Corporate Governance Code during the Reporting Period[146] - The roles of the Chairman and General Manager are separate, with Mr. Zhang Feng serving as the current Chairman[140] - The Company is in the process of identifying a suitable candidate to fill the vacancy of the General Manager[145] - Neptunus Bio-engineering confirmed compliance with Non-Competition Undertakings during the Reporting Period[132] - The Audit Committee reviewed the unaudited consolidated results of the Group for the Reporting Period[139] - The Company has adopted a code of conduct regarding securities transactions by Directors, confirming no transactions were conducted during the Reporting Period[133] Research and Development - Research and development costs for the period were RMB 6,897,000, an increase from RMB 5,320,000 in the previous year[42] - The Group's research and development efforts focus on internal demands and collaborations with external institutions, resulting in several new drugs and exclusive products with self-owned intellectual property rights[61] Market Strategy - Neptunus Zhongxin has implemented diversified marketing strategies and expanded its distributor coverage to navigate increasing regulatory and competitive pressures in the pharmaceutical industry[65] - The Group's pharmaceutical subsidiaries are actively strengthening management and collaborating directly with raw material suppliers to ensure production needs are met amid rising costs and regulatory pressures[66] Shareholding Structure - The controlling shareholder, Neptunus Bio-engineering, held approximately 73.51% of the entire issued share capital of the Company, with 70.38% directly held and 3.13% indirectly held through Neptunus Oriental[109] - Substantial shareholder Neptunus Bio-engineering holds 1,181,000,000 domestic shares, representing approximately 94.33% of all domestic shares and 70.38% of the Company's issued share capital[120] - Neptunus Group is deemed to be interested in 1,233,464,500 domestic shares, which is approximately 98.52% of all domestic shares and 73.51% of the Company's issued share capital[120] Compliance and Regulations - The Company and its subsidiaries have not adopted any share option scheme or granted any options, convertible securities, or warrants as of March 31, 2022[112] - The Company and its subsidiaries did not purchase, redeem, or sell any of the Company's listed securities during the Reporting Period[125] - As of March 31, 2022, the Directors and supervisors are not aware of any other persons holding interests or short positions in the shares of the Company[124]